{"id":"denosumab-ref","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Denosumab binds to RANKL, a key mediator of osteoclast differentiation and activation. By blocking the RANKL-RANK interaction, it reduces bone turnover and increases bone mineral density. This mechanism makes it effective for conditions characterized by excessive bone loss, such as osteoporosis and bone metastases.","oneSentence":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:01.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of skeletal-related events in patients with bone metastases from solid tumors"},{"name":"Treatment of osteoporosis in postmenopausal women and men at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT05419427","phase":"PHASE3","title":"Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Lambda Therapeutic Research Ltd.","startDate":"2021-11-11","conditions":"Osteoporosis, Postmenopausal","enrollment":552}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prolia"],"phase":"phase_3","status":"active","brandName":"Denosumab-Ref","genericName":"Denosumab-Ref","companyName":"Lambda Therapeutic Research Ltd.","companyId":"lambda-therapeutic-research-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption. Used for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of osteoporosis in postmenopausal women and men at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}